Antiviral Agents

• 

  Subject Areas on Research

  • "If I Get Cured, My Whole Quality of Life Will Change": Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C. 
  • 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. 
  • 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. 
  • 3-nitrotyrosine attenuates respiratory syncytial virus infection in human bronchial epithelial cell line. 
  • 4-oxatetradecanoic acid is fungicidal for Cryptococcus neoformans and inhibits replication of human immunodeficiency virus I. 
  • A 17-Year-Old Boy With Right Face Palsy, Left Leg Weakness, and Lytic Skull-Bone Lesions. 
  • A 40-year-old man with a perforated cheek. 
  • A Computational Model of Inhibition of HIV-1 by Interferon-Alpha. 
  • A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure. 
  • A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. 
  • A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. 
  • A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment. 
  • A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. 
  • A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. 
  • A fatal case of coronavirus disease 2019 in a patient with common variable immunodeficiency. 
  • A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses. 
  • A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. 
  • A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. 
  • A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. 
  • A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. 
  • A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. 
  • A rationalized approach to the treatment of patients infected with hepatitis B. 
  • A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response. 
  • A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. 
  • A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. 
  • ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations. 
  • Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. 
  • Activation and evasion of antiviral innate immunity by hepatitis C virus. 
  • Active cytomegalovirus particles in the eyes of an AIDS patient being treated with 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (Ganciclovir). 
  • Activity of Galidesivir in a Hamster Model of SARS-CoV-2. 
  • Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. 
  • Acute retinal necrosis following epidural steroid injections. 
  • Acyclovir in human immunodeficiency virus patients. 
  • Acyclovir or Aβ42 peptides attenuate HSV-1-induced miRNA-146a levels in human primary brain cells. 
  • Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination. 
  • Adefovir dipivoxil in chronic hepatitis B: history and current uses. 
  • Adenovirus infections in pediatric small bowel transplant recipients. 
  • Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers. 
  • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. 
  • Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia. 
  • Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. 
  • Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study. 
  • Advertisement breached code of practice 
  • Aerosolized ribavirin: the most expensive drug for pneumonia. 
  • Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment. 
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. 
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. 
  • Amino Acid-Based Poly(ester urea)s as a Matrix for Extended Release of Entecavir. 
  • An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. 
  • An Infection Control Program for a 2009 influenza A H1N1 outbreak in a university-based summer camp. 
  • An Update on Innate Immune Responses during SARS-CoV-2 Infection. 
  • An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. 
  • An inducible heat shock protein 70 small molecule inhibitor demonstrates anti-dengue virus activity, validating Hsp70 as a host antiviral target. 
  • An international perspective on hospitalized patients with viral community-acquired pneumonia. 
  • An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. 
  • Analysis of site performance in academic-based and community-based centers in the IDEAL Study. 
  • Anti-AIDS agents. 15. Synthesis and anti-HIV activity of dihydroseselins and related analogs. 
  • Anti-Acids Agents, 6. Salaspermic Acid, an Anti-HIV Principle from Tripterygium Wilfordii, and the Structure Activity Correlation with Its Related Compounds 
  • Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. 
  • Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. 
  • Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. 
  • Antiviral Effect of Retro-2.1 against Herpes Simplex Virus Type 2 In Vitro. 
  • Antiviral Effects of ABMA against Herpes Simplex Virus Type 2 In Vitro and In Vivo. 
  • Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus in vitro. 
  • Antiviral activity of mixed-valence rare earth borotungstate heteropoly blues against influenza virus in mice. 
  • Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. 
  • Antiviral effects of Retro-2cycl and Retro-2.1 against Enterovirus 71 in vitro and in vivo. 
  • Antiviral therapy for human immunodeficiency virus infection in children. 
  • Antivirals for adult patients hospitalized with SARS-CoV-2 infection: A randomized, Phase II/III, multicenter, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX - REVOLUTIOn: protocol and statistical analysis plan. 
  • Approach to the treatment-naïve patient with HCV genotype 1 infection. 
  • Are current therapies useful for the prevention of postherpetic neuralgia? A critical analysis of the literature. 
  • Assessing and restoring adaptive immunity to HSV, VZV, and HHV-6 in solid organ and hematopoietic cell transplant recipients. 
  • Assessing bioequivalence using genomic data. 
  • Assessment of pain in herpes zoster: lessons learned from antiviral trials. 
  • Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial. 
  • Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients. 
  • Associations Between Medicare Part D and Out-of-Pocket Spending, HIV Viral Load, Adherence, and ADAP Use in Dual Eligibles With HIV. 
  • Asymmetric Synthesis of 2'-C -Methyl-4'-selenonucleosides as Anti-Hepatitis C Virus Agents. 
  • Autoimmune hepatitis in a child with chronic hepatitis B virus infection. 
  • Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. 
  • Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. 
  • Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. 
  • Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. 
  • Benefits of Direct-Acting Antivirals for Hepatitis C. 
  • Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. 
  • Boceprevir for HCV in patients with HIV: where next? 
  • Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. 
  • Boceprevir for untreated chronic HCV genotype 1 infection. 
  • Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion. 
  • CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. 
  • CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. 
  • CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. 
  • CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. 
  • COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. 
  • Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. 
  • Cellular fatty acid synthase is required for late stages of HIV-1 replication. 
  • Cellular glycan modification by B3GAT1 broadly restricts influenza virus infection. 
  • Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. 
  • Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. 
  • Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo. 
  • Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? 
  • Chronic hepatitis C: an age wave of disease burden. 
  • Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care. 
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. 
  • Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. 
  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. 
  • Clinical outcomes in cytomegalovirus-positive Posner-Schlossman syndrome patients treated with topical ganciclovir therapy. 
  • Clinical presentation and response to treatment of novel influenza A H1N1 in a university-based summer camp population. 
  • Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. 
  • Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. 
  • Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. 
  • Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009. 
  • Commentary: The Field Moves Forward. 
  • Comments on cochrane review on direct-acting antivirals for hepatitis C. 
  • Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals. 
  • Conjunctival pseudotumor caused by herpes simplex virus infection. 
  • Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. 
  • Curing hepatitis C virus (HCV) after organ transplantation: Increased risk of rejection following HCV elimination. 
  • Current and future treatment of HIV infection. 
  • Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. 
  • Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients. 
  • Cutaneous herpes simplex virus infection of guinea pigs as a model for antiviral chemotherapy. 
  • Cytomegalovirus Infection Management in Multivisceral and Intestinal Transplant: A Dual Institution Study. 
  • Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients. 
  • Cytomegalovirus encephalomyelitis: MR imaging findings documenting response to ganciclovir therapy. 
  • Cytomegalovirus infection. 
  • Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. 
  • Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis. 
  • Cytomegalovirus retinitis associated with Hodgkin's disease. 
  • Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance. 
  • DNA polymerases versus HIV reverse transcriptase in AIDS therapy. 
  • DNA topoisomerases as potential targets of antiviral action. 
  • Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. 
  • Definition and management of anemia in patients infected with hepatitis C virus. 
  • Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. 
  • Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. 
  • Delayed vs initial cytomegalovirus prophylaxis after kidney transplantation. 
  • Dengue Virus Targets Nrf2 for NS2B3-Mediated Degradation Leading to Enhanced Oxidative Stress and Viral Replication. 
  • Design and Synthesis of Quinolizidine Derivatives as Influenza Virus and HIV-1 Inhibitors. 
  • Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). 
  • Design, synthesis and structure relationships of new N,N',N",N"'-tetrakis (omega-amino alkyl) tetraazamacrocycles. 
  • Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza. 
  • Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay. 
  • Development of a liquid chromatography-tandem mass spectrometry assay of six antimicrobials in plasma for pharmacokinetic studies in premature infants. 
  • Development of fatal acute liver failure in HIV-HBV coinfected patients. 
  • Diagnosis and Treatment of Acute Retinal Necrosis: A Report by the American Academy of Ophthalmology. 
  • Diagnosis and antenatal management of congenital cytomegalovirus infection. 
  • Diagnosis and treatment of chronic hepatitis C infection. 
  • Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. 
  • Differential chromatin accessibility in peripheral blood mononuclear cells underlies COVID-19 disease severity prior to seroconversion. 
  • Differential inhibition of HIV-1 cell binding and HIV-1-induced syncytium formation by low molecular weight sulphated polysaccharides. 
  • Differential regulation of primary and memory CD8 T cell immune responses by diacylglycerol kinases. 
  • Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. 
  • Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. 
  • Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. 
  • Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination. 
  • Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do? 
  • Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. 
  • Dislocated ganciclovir implant from use of a nylon fixation suture. 
  • Disseminated Adenovirus Infection After Combined Liver-Kidney Transplantation. 
  • Dobson backed NICE ruling on flu drug. 
  • Does hepatitis B surface antigen kinetics, including both decline and reaching a threshold, improve prediction of response? 
  • Domino liver transplantation in maple syrup urine disease: a case report and review of the literature. 
  • Donor derived HSV hepatitis in a kidney transplant recipient leading to liver fibrosis and portal hypertension. 
  • Driving factors in amiloride recognition of HIV RNA targets. 
  • Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. 
  • Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. 
  • Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. 
  • EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. 
  • Early detection of cerebrovascular pathology and protective antiviral immunity by MRI. 
  • Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. 
  • Early versus delayed initiation of cytomegalovirus prophylaxis after liver transplant. 
  • Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. 
  • Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. 
  • Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: a self-controlled prospective study. 
  • Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. 
  • Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. 
  • Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. 
  • Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. 
  • Effects of Sofosbuvir-Based Hepatitis C Treatment Regimens on Calcineurin Inhibitor Dosing in Liver and Kidney Transplant Recipients. 
  • Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. 
  • Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. 
  • Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. 
  • Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. 
  • Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. 
  • Efficient cross-priming of antiviral CD8+ T cells by antigen donor cells is GRP94 independent. 
  • Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets. 
  • Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. 
  • Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin. 
  • Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. 
  • Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process. 
  • Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies. 
  • Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. 
  • Endogenous salivary inhibitors of human immunodeficiency virus. 
  • Epidemiology of respiratory syncytial virus in various regions within North Carolina during multiple seasons. 
  • Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. 
  • Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. 
  • Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. 
  • Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1. 
  • Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus. 
  • Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas: A Lesion Associated With Diverse Immunodeficiency Settings. 
  • Exposure-safety relationship for acyclovir in the treatment of neonatal herpes simplex virus disease. 
  • Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. 
  • Extracorporeal membrane oxygenation for severe refractory respiratory failure secondary to 2009 H1N1 influenza A. 
  • Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers. 
  • Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. 
  • Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1. 
  • Factors influencing the participation of gastroenterologists and hepatologists in clinical research. 
  • FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus. 
  • Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. 
  • Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19-Reply. 
  • Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. 
  • From high-throughput to therapeutic: host-directed interventions against influenza viruses. 
  • Further characterization of the oncornavirus inactivating factor in normal mouse serum. 
  • Future therapy of hepatitis C. 
  • Future trends in managing hepatitis C. 
  • Genetic dissection of systemic acquired resistance. 
  • Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection. 
  • Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. 
  • Genomic RNA Elements Drive Phase Separation of the SARS-CoV-2 Nucleocapsid. 
  • Genotype 3 Infection: The Last Stand of Hepatitis C Virus. 
  • Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. 
  • Growth factors during HCV therapy may be "cost-effective", but are they "effective"? 
  • HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. 
  • HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients. 
  • Hemorrhagic Herpes Simplex Virus Type 1 Nephritis: An Unusual Cause of Acute Allograft Dysfunction. 
  • Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. 
  • Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. 
  • Hepatitis B and C viruses in infants and young children. 
  • Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management. 
  • Hepatitis B virus viral load and treatment decision. 
  • Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. 
  • Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. 
  • Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A. 
  • Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. 
  • Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients? 
  • Hepatitis C and depressive symptoms: psychological and social factors matter more than liver injury. 
  • Hepatitis C and steatosis. 
  • Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. 
  • Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. 
  • Hepatitis C in Pregnancy: Review of Current Knowledge and Updated Recommendations for Management. 
  • Hepatitis C in pregnancy: screening, treatment, and management. 
  • Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. 
  • Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. 
  • Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. 
  • Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. 
  • Hepatitis C virus-related cryoglobulinemic vasculitis: emerging trends in therapy. 
  • Herpes Zoster. 
  • Herpes Zoster. 
  • Herpes simplex virus hepatitis after renal transplantation. 
  • Herpes virus infections, HIV, and disease progression. Guarded optimism. 
  • Herpes zoster and postherpetic neuralgia in older adults. 
  • Herpes zoster in the elderly: issues related to geriatrics. 
  • Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. 
  • High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients. 
  • How RNA modifications regulate the antiviral response. 
  • Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus. 
  • Human Cytomegalovirus Infection Primes Fetal Natural Killer Cells for Fc-Mediated Antiviral Defense. 
  • Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned. 
  • Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. 
  • ICP34.5-dependent and -independent activities of salubrinal in herpes simplex virus-1 infected cells. 
  • IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. 
  • IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR. 
  • IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. 
  • IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. 
  • IL28B in the era of direct-acting antivirals for hepatitis C. 
  • IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. 
  • ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. 
  • ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. 
  • Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui. 
  • Immune correlates of HIV-1 reservoir cell decline in early-treated infants. 
  • Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. 
  • Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. 
  • Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals. 
  • Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence. 
  • Impact of prophylactic oseltamivir on INR in patients on stable warfarin therapy. 
  • Implementation of a rapid influenza A/B and RSV direct molecular assay improves emergency department oseltamivir use in paediatric patients. 
  • Importance of vertebrate viruses for choosing hand antiseptics with virucidal efficacy. 
  • Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. 
  • Improving Access to Hepatitis C Treatment Using Clinical Pharmacist Services in an Uninsured, At-Risk Population at a Community Health Center. 
  • In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. 
  • In the clinic. Hepatitis C. 
  • In the clinic. Hepatitis C. 
  • In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. 
  • Inactivation of murine xenotropic oncornavirus by normal mouse sera is not immunoglobulin-mediated. 
  • Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection. 
  • Incidence of cytomegalovirus disease in renal transplantation without antilymphocyte induction: is prophylaxis necessary? 
  • Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy. 
  • Infection prophylaxis in pancreas transplant recipients. 
  • Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans. 
  • Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. 
  • Influenza viruses that require 10 genomic segments as antiviral therapeutics. 
  • Inhibition of HIV-1 proviral DNA synthesis and RNA accumulation by mismatched dsRNA. 
  • Inhibition of glycosylation of bovine herpesvirus 1 glycoproteins by the thymidine analog (E)-5-(2 Bromovinyl)-2'-deoxyuridine. 
  • Inhibition of human immunodeficiency virus type 1 entry by a binding domain of Porphyromonas gingivalis gingipain. 
  • Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid. 
  • Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. 
  • Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication. 
  • Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. 
  • Innate immune signaling in trophoblast and decidua organoids defines differential antiviral defenses at the maternal-fetal interface. 
  • Innovations in Heart Transplantation: A Review. 
  • Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. 
  • Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. 
  • Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo. 
  • Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. 
  • Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. 
  • Interferon lambda protects the female reproductive tract against Zika virus infection. 
  • Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon. 
  • Interferon-Inducible E3 Ligase RNF213 Facilitates Host-Protective Linear and K63-Linked Ubiquitylation of Toxoplasma gondii Parasitophorous Vacuoles. 
  • Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. 
  • Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. 
  • Is the HCV pipeline heading in the right direction? 
  • Kidney and pancreas transplantation at Wake Forest University Baptist Medical Center. 
  • Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. 
  • Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. 
  • Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. 
  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. 
  • Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. 
  • Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. 
  • Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. 
  • Leflunomide for polyomavirus type BK nephropathy. 
  • Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. 
  • Leveraging the advances in HIV for COVID-19. 
  • Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. 
  • Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. 
  • Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. 
  • Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment. 
  • Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. 
  • Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. 
  • Lost in translation? IL28B's discovery and the journey back to the patient. 
  • Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. 
  • Making it happen: managed care considerations in vanquishing hepatitis C. 
  • Management of bronchiolitis in infants and children. 
  • Management of hepatitis C virus infection: the basics. 
  • Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. 
  • Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. 
  • Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. 
  • Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. 
  • Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. 
  • Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. 
  • Mechanisms of MAVS regulation at the mitochondrial membrane. 
  • Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. 
  • Methadone Disposition: Implementing Lessons Learned. 
  • Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus. 
  • Mismatched dsRNA (ampligen) induces protection against genomic variants of the human immunodeficiency virus type 1 (HIV-1) in a multiplicity of target cells. 
  • Mixed model analysis of censored longitudinal data with flexible random-effects density. 
  • Model synthesis of nucleoside boranophosphoramidate with amino acid for prodrug purpose. 
  • Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. 
  • NICE to rule on influenza flu drug zanamivir. 
  • Natural history and treatment of herpes zoster. 
  • Natural history of neonatal herpes simplex virus infections in the acyclovir era. 
  • Natural products and chronic hepatitis C virus. 
  • Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. 
  • Nelfinavir inhibits maturation and export of herpes simplex virus 1. 
  • Neuraxial Procedures in COVID-19-Positive Parturients: A Review of Current Reports. 
  • Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012. 
  • New Therapeutics for Hepatitis B: The Road to Cure. 
  • New therapies for chronic hepatitis C virus infection. 
  • Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. 
  • Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C. 
  • Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes. 
  • Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression. 
  • Nucleic acid scavenging polymers inhibit extracellular DNA-mediated innate immune activation without inhibiting anti-viral responses. 
  • Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. 
  • Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation. 
  • Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. 
  • Oral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients. 
  • Orthogonal genome-wide screens of bat cells identify MTHFD1 as a target of broad antiviral therapy. 
  • Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. 
  • Outcomes of COVID-19 in patients with CLL: a multicenter international experience. 
  • Outcomes of a Negative Rapid Influenza Diagnostic Test in Pregnant Women. 
  • Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. 
  • Overcoming barriers to care for hepatitis C. 
  • PHOTON-2: hope for patients with HIV and HCV co-infection? 
  • PKR Binds Enterovirus IRESs, Displaces Host Translation Factors, and Impairs Viral Translation to Enable Innate Antiviral Signaling. 
  • PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. 
  • Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. 
  • Pandemic (H1N1) 2009 and oseltamivir resistance in hematology/oncology patients. 
  • Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. 
  • Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. 
  • Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C). 
  • Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. 
  • Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. 
  • Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. 
  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. 
  • Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients. 
  • Penile erosions associated with foscarnet therapy in a child. 
  • Pericarditis mediated by respiratory syncytial virus in a hematopoietic stem cell transplant patient. 
  • Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. 
  • Perinatal cytomegalovirus and varicella zoster virus infections: epidemiology, prevention, and treatment. 
  • Persulfated molecular umbrellas as anti-HIV and anti-HSV agents. 
  • Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. 
  • Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. 
  • Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. 
  • Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. 
  • Pharmacokinetics of the ganciclovir implant in the silicone-filled eye. 
  • Pharmacologic treatment of bronchiolitis in infants and children: a systematic review. 
  • Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. 
  • Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. 
  • Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. 
  • Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. 
  • Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. 
  • Physicians' stated trade-off preferences for chronic hepatitis B treatment outcomes in Germany, France, Spain, Turkey, and Italy. 
  • Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. 
  • Population pharmacokinetics of intravenous acyclovir in preterm and term infants. 
  • Post-transcriptional regulation of antiviral gene expression by N6-methyladenosine. 
  • Postinfection therapy of arbovirus infections in mice. 
  • Potential Antiviral Strategy Exploiting Dependence of SARS-CoV-2 Replication on Lysosome-Based Pathway. 
  • Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. 
  • Practice patterns and incidence of adenovirus infection in allogeneic hematopoietic cell transplant recipients: Multicenter survey of transplant centers in the United States. 
  • Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. 
  • Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin. 
  • Predictors of consent to pharmacogenomics testing in the IDEAL study. 
  • Predictors of depression recovery in HIV-infected individuals managed through measurement-based care in infectious disease clinics. 
  • Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up. 
  • Premature Rupture of Membranes with Concurrent Viral Infection. 
  • Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide. 
  • Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. 
  • Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. 
  • Prospects for treatment of human retrovirus-associated diseases. 
  • Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection. 
  • Protein synthesis-dependent potentiation by thyroxine of antiviral activity of interferon-gamma. 
  • Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort. 
  • Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. 
  • Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. 
  • Pure red cell aplasia following pegylated interferon alpha treatment. 
  • Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. 
  • RIPK3: Beyond Necroptosis. 
  • Racial differences in hepatitis C treatment eligibility. 
  • Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. 
  • Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1. 
  • Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. 
  • Reading, writing, and modulating genetic information with boranophosphate mimics of nucleotides, DNA, and RNA. 
  • Real-World Effectiveness of DAA Therapies in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection: 996 Veterans Can't Be Wrong. 
  • Real-world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high-risk donor seropositive/recipient seronegative (D+R-) liver transplant recipients (LTxR). 
  • Recommendations for Prevention and Control of Influenza in Children, 2021-2022. 
  • Recommendations for the management of herpes zoster. 
  • Reduced Alcohol Use Is Sustained in Patients Provided Alcohol-Related Counseling During Direct-Acting Antiviral Therapy for Hepatitis C. 
  • Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. 
  • Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection. 
  • Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. 
  • Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data. 
  • Remdesivir for the Treatment of Covid-19 - Final Report. 
  • Remdesivir: a pendulum in a pandemic. 
  • Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. 
  • Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)". 
  • Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity. 
  • Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. 
  • Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. 
  • Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis. 
  • Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group (ACTG). 
  • Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper? 
  • Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents. 
  • Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. 
  • Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. 
  • Risks and outcomes of adenovirus disease in pediatric hematopoietic stem cell transplant recipients-Comparison of current antiviral treatment options. 
  • Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C. 
  • SARS-CoV-2 Variants in Patients with Immunosuppression. 
  • Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. 
  • Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. 
  • Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. 
  • Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. 
  • Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. 
  • Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults. 
  • Safety of High-dose Acyclovir in Infants With Suspected and Confirmed Neonatal Herpes Simplex Virus Infections. 
  • Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. 
  • Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. 
  • Sarcoidosis induced by interferon therapy. 
  • Schwann cell influence on motor neuron regeneration accuracy. 
  • Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus. 
  • Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I. 
  • Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus in vitro. 
  • Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles. 
  • Semiparametric estimation of treatment effect in a pretest-posttest study. 
  • Sensitivity Analysis of a Pharmacokinetic Model of Vaginal Anti-HIV Microbicide Drug Delivery. 
  • Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression. 
  • Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. 
  • Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. 
  • Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. 
  • Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. 
  • Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. 
  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. 
  • Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. 
  • Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. 
  • Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. 
  • Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. 
  • Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. 
  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. 
  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. 
  • Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment. 
  • Stat1 acetylation inhibits inducible nitric oxide synthase expression in interferon-gamma-treated RAW264.7 murine macrophages. 
  • Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. 
  • Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective. 
  • Strategies of antiretroviral therapy in adults. 
  • Structural Optimizations of Thieno[3,2-b]pyrrole Derivatives for the Development of Metabolically Stable Inhibitors of Chikungunya Virus. 
  • Successes and Challenges on the Road to Cure Hepatitis C. 
  • Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir. 
  • Sudden Unilateral Decrease in Vision in a Healthy Middle-aged Man. 
  • Sudden sensorineural hearing loss: a viral etiology? 
  • Suksdorfin: an anti-HIV principle from Lomatium suksdorfii, its structure-activity correlation with related coumarins, and synergistic effects with anti-AIDS nucleosides. 
  • Supportive Interventions During Treatment of Chronic Hepatitis C: A Review of the Literature. 
  • Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group. 
  • Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial. 
  • Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. 
  • Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. 
  • Synthesis and biological evaluation of an 123I-labeled bicyclic nucleoside analogue (BCNA) as potential SPECT tracer for VZV-tk reporter gene imaging. 
  • Synthesis of prodrug candidates: conjugates of amino acid with nucleoside boranophosphate. 
  • Systemic antiviral drugs used in ophthalmology. 
  • TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2. 
  • Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. 
  • Taste and smell losses in HIV infected patients. 
  • Telaprevir for previously treated chronic HCV infection. 
  • Telaprevir for previously untreated chronic hepatitis C virus infection. 
  • Telaprevir for the treatment of chronic hepatitis C infection. 
  • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. 
  • Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. 
  • Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. 
  • The AIDS epidemic: lessons learned? 
  • The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo. 
  • The clinical management of HCV in the HIV-infected patient. 
  • The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA. 
  • The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. 
  • The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. 
  • The mitochondrial targeting chaperone 14-3-3ε regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity. 
  • The natural history of hepatitis C viral infection. 
  • The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. 
  • The pH Dependence of Niclosamide Solubility, Dissolution, and Morphology: Motivation for Potentially Universal Mucin-Penetrating Nasal and Throat Sprays for COVID19, its Variants and other Viral Infections. 
  • The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. 
  • The protease inhibitor era: an opportunity to improve the quality of care. 
  • The rapid evolution of treatment strategies for hepatitis C. 
  • The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. 
  • The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. 
  • The use of complementary and alternative medicine by patients with chronic hepatitis C. 
  • Therapy of acute and fulminant hepatitis B. 
  • Tinkering and tailoring with HCV therapy: can we get away with less? 
  • Topical ganciclovir treatment in patients with cytomegalovirus endotheliitis receiving penetrating keratoplasty. 
  • Transcriptional responses define dysregulated immune activation in Hepatitis C (HCV)-naïve recipients of HCV-infected donor kidneys. 
  • Transmission of HIV by antigen presenting cells during T-cell activation: prevention by 3'-azido-3'-deoxythymidine. 
  • Treating HCV Infection: It Doesn't Get Much Better Than This. 
  • Treatment of HCV infection by targeting microRNA. 
  • Treatment of acute hepatitis C infection: more pieces of the puzzle? 
  • Treatment of acute hepatitis C with interferon alfa-2b. 
  • Treatment of chronic hepatitis C in blacks and non-Hispanic whites. 
  • Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. 
  • Treatment of hepatitis C in special populations. 
  • Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir. 
  • Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir. 
  • Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study. 
  • Trends in hepatitis C treatment uptake in the United States. 
  • Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trial. 
  • Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses. 
  • Two new ursane-type triterpenoid saponins from Elsholtzia bodinieri. 
  • Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. 
  • Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection. 
  • Uncontrolled Epstein-Barr Virus as an Atypical Presentation of Deficiency in ADA2 (DADA2). 
  • Unethical studies of ivermectin for covid-19. 
  • Up-regulation of GRP78 and antiapoptotic signaling in murine peritoneal macrophages exposed to insulin. 
  • Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication. 
  • Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. 
  • Urolithiasis under atazanavir boosted and tenofovir therapy: a case report. 
  • Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis. 
  • Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient. 
  • Use of antiretroviral therapy in children and pregnant women. 
  • Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel. 
  • Using "old" medications to fight new COVID-19: Re-purposing with a purpose. 
  • Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. 
  • Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. 
  • Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. 
  • Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. 
  • Variation in interferon sensitivity and induction among strains of eastern equine encephalitis virus. 
  • Varicella during pregnancy. Maternal and fetal effects. 
  • Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration. 
  • Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. 
  • Viral infections after renal transplantation. 
  • Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. 
  • Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. 
  • Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. 
  • Virology under the Microscope-a Call for Rational Discourse. 
  • Virology, Epidemiology, Pathogenesis, and Control of COVID-19. 
  • Viruses in the treatment of brain tumors. 
  • Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity? 
  • Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge. 
  • [A prospective study of histological changes after AraAMP treatment in patients with chronic hepatitis B infection]. 
  • [Experimental studies on human lung cancer gene-therapy with HSV-TK/GCV system]. 
  • [Organ transplantation infection and its prevention and treatment]. 
  • [Synthesis and anti-influenza virus activities of heteropoly compounds containing rare earth elements]. 
  • alpha-Defensin inhibits influenza virus replication by cell-mediated mechanism(s). 
• 

  Keywords of People

  • Choi, Steven Sok, Associate Professor of Medicine, Medicine, Gastroenterology
  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Heaton, Nicholas Scott, Associate Professor of Molecular Genetics and Microbiology, Cell Biology
  • Tsalik, Ephraim, Adjunct Associate Professor in the Department of Medicine, Medicine, Infectious Diseases
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology